Last reviewed · How we verify
NCT04326088
Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer
trial testing Reconstruction group in Head and Neck Cancer in 2,004 participants. Completed in 31 March 2019.
15 December 2018
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,004 |
| Start date | 1 April 2018 |
| Primary completion | 15 December 2018 |
| Estimated completion | 31 March 2019 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Reconstruction group
- Recurrent group
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Recurrent Cancer — all drugs for Recurrent Cancer →
- Surgery--Complications — all drugs for Surgery--Complications →
Sponsor
Chang Gung Memorial Hospital
Who can join
Adults 20 to 100, any sex, with Head and Neck Cancer or Recurrent Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed to investigate the outcome of free-flap reconstruction surgery following head and neck cancer resection between primary and recurrent head and neck cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04326088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04326088 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 30 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04326088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing